---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-297454"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2026-07-07T20:04:11+00:00"
generated_at: "2026-07-07T20:05:37.079514+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Vor BioPharma appoints David Zaccardelli to board; director Andrew Levin resigns

## Summary
- Andrew Levin resigned as director effective July 6, 2026; no disagreement with the company.
- David Zaccardelli appointed as independent Class II director, term until 2029 annual meeting.
- Zaccardelli is former CEO of Verona Pharma (acquired by Merck 2025), Dova, and Cempra.
- He receives standard non-employee director compensation: $40k annual cash retainer, initial option grant of up to 68k shares or $700k.
- No material transactions or arrangements exist between Zaccardelli and the company.

## SEC filing metadata
- accession: 0001193125-26-297454
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2026-07-07T20:04:11+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312526297454/0001193125-26-297454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312526297454/vor-20260706.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-297454
- JSON: https://secwatch.observer/filing/0001193125-26-297454.json
- Plain text: https://secwatch.observer/filing/0001193125-26-297454.txt

## Key facts
- Executive change
  Andrew Levin resigned as Director at Vor Biopharma Inc..
  - Action: resigned
  - Role: Director
  source text: On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312526297454/0001193125-26-297454-index.htm
- Executive change
  David Zaccardelli was appointed as Director at Vor Biopharma Inc..
  - Action: appointed
  - Role: Director
  source text: On July 7, 2026, the Board appointed David Zaccardelli, Pharm.D. to the vacancy created by Dr. Levin’s resignation, to serve on the Board as an independent Class II director until the Company’s 2029 annual meeting of stockholders and until his successor is duly elected and qualified or his earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312526297454/0001193125-26-297454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.